PriceTargets.com logo

U.S. Physical Therapy - USPH Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $105.00
  • Forecasted Upside: 11.50%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$94.17 As of 11/20/2024 01:00 AM ET
▲ +3.54 (3.91%)

This chart shows the closing price for USPH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New U.S. Physical Therapy Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for USPH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for USPH

Analyst Price Target is $105.00
▲ +11.50% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for U.S. Physical Therapy in the last 3 months. The average price target is $105.00, with a high forecast of $117.00 and a low forecast of $90.00. The average price target represents a 11.50% upside from the last price of $94.17.

This chart shows the closing price for USPH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 3 investment analysts is to moderate buy stock in U.S. Physical Therapy. This rating has held steady since September 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/7/2024Barrington ResearchReiterated RatingOutperform ➝ Outperform$108.00 ➝ $108.00
10/9/2024Barrington ResearchReiterated RatingOutperform ➝ Outperform$108.00 ➝ $108.00
10/7/2024Bank of AmericaReiterated RatingBuy ➝ Neutral$114.00 ➝ $90.00
9/20/2024Barrington ResearchReiterated RatingOutperform ➝ Outperform$108.00 ➝ $108.00
8/15/2024Barrington ResearchLower TargetOutperform ➝ Outperform$122.00 ➝ $108.00
5/9/2024Barrington ResearchReiterated RatingOutperform ➝ Outperform$122.00 ➝ $122.00
3/13/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$99.00 ➝ $117.00
3/1/2024Barrington ResearchBoost TargetOutperform ➝ Outperform$120.00 ➝ $122.00
1/3/2024Barrington ResearchBoost TargetOutperform ➝ Outperform$111.00 ➝ $120.00
11/17/2023JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$108.00 ➝ $99.00
11/9/2023Barrington ResearchLower TargetOutperform ➝ Outperform$124.00 ➝ $111.00
9/22/2023JPMorgan Chase & Co.Initiated CoverageOverweight$108.00
9/19/2023CJS SecuritiesUpgradeMarket Perform ➝ Outperform
8/14/2023Barrington ResearchBoost TargetOutperform ➝ Outperform$116.00 ➝ $124.00
6/30/2023Bank of AmericaInitiated CoverageBuy$138.00
5/5/2023Barrington ResearchBoost Target$110.00 ➝ $116.00
2/24/2023Barrington ResearchBoost TargetOutperform$107.00 ➝ $110.00
2/25/2022Barrington ResearchLower Target$144.00 ➝ $123.00
12/14/2021CJS SecuritiesUpgradeMarket Perform ➝ Outperform$120.00
11/22/2021SidotiUpgradeNeutral ➝ Buy
8/6/2021Barrington ResearchBoost TargetOutperform$130.00 ➝ $139.00
5/7/2021Barrington ResearchUpgradeMarket Perform ➝ Outperform$130.00
5/3/2021Jefferies Financial GroupUpgradeHold ➝ Buy$130.00 ➝ $135.00
3/4/2021Barrington ResearchReiterated RatingOutperform ➝ Market Perform
2/26/2021Barrington ResearchDowngradeOutperform ➝ Market Perform
8/7/2020Barrington ResearchBoost TargetOutperform$95.00 ➝ $100.00
6/8/2020Barrington ResearchBoost TargetOutperform$84.00 ➝ $95.00
4/30/2020SidotiDowngradeBuy ➝ Neutral
3/27/2020SidotiLower TargetBuy$128.00 ➝ $80.00
3/17/2020William BlairDowngradeOutperform ➝ Hold
3/11/2020SidotiUpgradeNeutral ➝ Buy$128.00
2/28/2020Barrington ResearchLower TargetOutperform$130.00 ➝ $120.00
1/31/2020William BlairReiterated RatingBuy
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.71 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024
  • 15 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2024
  • 11 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 8 very positive mentions
  • 10 positive mentions
  • 6 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2024
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 9 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/21/2024
  • 13 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 13 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

U.S. Physical Therapy logo
U.S. Physical Therapy, Inc. operates outpatient physical therapy clinics. The company operates through Physical Therapy Operations and Industrial Injury Prevention Services segments. The company provides pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. It offers industrial injury prevention services, including onsite injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments through physical therapists and specialized certified athletic trainers for Fortune 500 companies, and other clients comprising insurers and their contractors. U.S. Physical Therapy, Inc. was founded in 1990 and is based in Houston, Texas.
Read More

Today's Range

Now: $94.17
Low: $90.85
High: $95.44

50 Day Range

MA: $84.68
Low: $77.48
High: $97.10

52 Week Range

Now: $94.17
Low: $76.18
High: $113.63

Volume

224,928 shs

Average Volume

92,797 shs

Market Capitalization

$1.42 billion

P/E Ratio

100.18

Dividend Yield

1.96%

Beta

1.38

Frequently Asked Questions

What sell-side analysts currently cover shares of U.S. Physical Therapy?

The following Wall Street research analysts have issued research reports on U.S. Physical Therapy in the last twelve months: Bank of America Co., Barrington Research, JPMorgan Chase & Co., and StockNews.com.
View the latest analyst ratings for USPH.

What is the current price target for U.S. Physical Therapy?

0 Wall Street analysts have set twelve-month price targets for U.S. Physical Therapy in the last year. Their average twelve-month price target is $105.00, suggesting a possible upside of 11.5%. JPMorgan Chase & Co. has the highest price target set, predicting USPH will reach $117.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $90.00 for U.S. Physical Therapy in the next year.
View the latest price targets for USPH.

What is the current consensus analyst rating for U.S. Physical Therapy?

U.S. Physical Therapy currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for USPH.

What other companies compete with U.S. Physical Therapy?

Other companies that are similar to U.S. Physical Therapy include Select Medical, Acadia Healthcare, Petco Health and Wellness, Brookdale Senior Living and Community Health Systems. Learn More about companies similar to U.S. Physical Therapy.

How do I contact U.S. Physical Therapy's investor relations team?

U.S. Physical Therapy's physical mailing address is 1300 WEST SAM HOUSTON PARKWAY SUITE 300, HOUSTON TX, 77042. The company's listed phone number is (713) 297-7000 and its investor relations email address is [email protected]. The official website for U.S. Physical Therapy is www.usph.com. Learn More about contacing U.S. Physical Therapy investor relations.